Literature DB >> 22618924

Association between treated and untreated obstructive sleep apnea and risk of hypertension.

José M Marin1, Alvar Agusti, Isabel Villar, Marta Forner, David Nieto, Santiago J Carrizo, Ferran Barbé, Eugenio Vicente, Ying Wei, F Javier Nieto, Sanja Jelic.   

Abstract

CONTEXT: Systemic hypertension is prevalent among patients with obstructive sleep apnea (OSA). Short-term studies indicate that continuous positive airway pressure (CPAP) therapy reduces blood pressure in patients with hypertension and OSA.
OBJECTIVE: To determine whether CPAP therapy is associated with a lower risk of incident hypertension. DESIGN, SETTING, AND PARTICIPANTS: A prospective cohort study of 1889 participants without hypertension who were referred to a sleep center in Zaragoza, Spain, for nocturnal polysomnography between January 1, 1994, and December 31, 2000. Incident hypertension was documented at annual follow-up visits up to January 1, 2011. Multivariable models adjusted for confounding factors, including change in body mass index from baseline to censored time, were used to calculate hazard ratios (HRs) of incident hypertension in participants without OSA (controls), with untreated OSA, and in those treated with CPAP therapy according to national guidelines. MAIN OUTCOME MEASURE: Incidence of new-onset hypertension.
RESULTS: During 21,003 person-years of follow-up (median, 12.2 years), 705 cases (37.3%) of incident hypertension were observed. The crude incidence of hypertension per 100 person-years was 2.19 (95% CI, 1.71-2.67) in controls, 3.34 (95% CI, 2.85-3.82) in patients with OSA ineligible for CPAP therapy, 5.84 (95% CI, 4.82-6.86) in patients with OSA who declined CPAP therapy, 5.12 (95% CI, 3.76-6.47) in patients with OSA nonadherent to CPAP therapy, and 3.06 (95% CI, 2.70-3.41) in patients with OSA and treated with CPAP therapy. Compared with controls, the adjusted HRs for incident hypertension were greater among patients with OSA ineligible for CPAP therapy (1.33; 95% CI, 1.01-1.75), among those who declined CPAP therapy (1.96; 95% CI, 1.44-2.66), and among those nonadherent to CPAP therapy (1.78; 95% CI, 1.23-2.58), whereas the HR was lower in patients with OSA who were treated with CPAP therapy (0.71; 95% CI, 0.53-0.94).
CONCLUSION: Compared with participants without OSA, the presence of OSA was associated with increased adjusted risk of incident hypertension; however, treatment with CPAP therapy was associated with a lower risk of hypertension.

Entities:  

Mesh:

Year:  2012        PMID: 22618924      PMCID: PMC4657563          DOI: 10.1001/jama.2012.3418

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  31 in total

1.  Population-based study of sleep-disordered breathing as a risk factor for hypertension.

Authors:  T Young; P Peppard; M Palta; K M Hla; L Finn; B Morgan; J Skatrud
Journal:  Arch Intern Med       Date:  1997 Aug 11-25

2.  Applications of multiple imputation to the analysis of censored regression data.

Authors:  G C Wei; M A Tanner
Journal:  Biometrics       Date:  1991-12       Impact factor: 2.571

3.  [Treatment of sleep apnea-hypoapnea syndrome].

Authors:  J M Montserrat; J Amilibia; F Barbé; F Capote; J Durán; N G Mangado; A Jiménez; J M Marín; F Masa; J Teran
Journal:  Arch Bronconeumol       Date:  1998-04       Impact factor: 4.872

4.  Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study.

Authors:  Jose M Marin; Santiago J Carrizo; Eugenio Vicente; Alvar G N Agusti
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

5.  Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women.

Authors:  T Young; L Evans; L Finn; M Palta
Journal:  Sleep       Date:  1997-09       Impact factor: 5.849

6.  Sympathetic activity in obese subjects with and without obstructive sleep apnea.

Authors:  K Narkiewicz; P J van de Borne; R L Cooley; M E Dyken; V K Somers
Journal:  Circulation       Date:  1998-08-25       Impact factor: 29.690

7.  Endothelial function in obstructive sleep apnea and response to treatment.

Authors:  Mary S M Ip; Hung-Fat Tse; Bing Lam; Kenneth W T Tsang; Wah-Kit Lam
Journal:  Am J Respir Crit Care Med       Date:  2003-10-09       Impact factor: 21.405

8.  Sleep apnea and hypertension. A population-based study.

Authors:  K M Hla; T B Young; T Bidwell; M Palta; J B Skatrud; J Dempsey
Journal:  Ann Intern Med       Date:  1994-03-01       Impact factor: 25.391

9.  The occurrence of sleep-disordered breathing among middle-aged adults.

Authors:  T Young; M Palta; J Dempsey; J Skatrud; S Weber; S Badr
Journal:  N Engl J Med       Date:  1993-04-29       Impact factor: 91.245

10.  High prevalence of hypertension in sleep apnea patients independent of obesity.

Authors:  J T Carlson; J A Hedner; H Ejnell; L E Peterson
Journal:  Am J Respir Crit Care Med       Date:  1994-07       Impact factor: 21.405

View more
  229 in total

1.  CPAP treatment supported by telemedicine does not improve blood pressure in high cardiovascular risk OSA patients: a randomized, controlled trial.

Authors:  Monique Mendelson; Isabelle Vivodtzev; Renaud Tamisier; David Laplaud; Sonia Dias-Domingos; Jean-Philippe Baguet; Laurent Moreau; Christian Koltes; Léonidas Chavez; Gilles De Lamberterie; Frédéric Herengt; Patrick Levy; Patrice Flore; Jean-Louis Pépin
Journal:  Sleep       Date:  2014-11-01       Impact factor: 5.849

Review 2.  Phosphinic peptides as zinc metalloproteinase inhibitors.

Authors:  V Dive; D Georgiadis; M Matziari; A Makaritis; F Beau; P Cuniasse; A Yiotakis
Journal:  Cell Mol Life Sci       Date:  2004-08       Impact factor: 9.261

Review 3.  New developments in the use of positive airway pressure for obstructive sleep apnea.

Authors:  Lucas M Donovan; Schafer Boeder; Atul Malhotra; Sanjay R Patel
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

4.  Treatment of obstructive sleep apnea alters cancer-associated transcriptional signatures in circulating leukocytes.

Authors:  Sina A Gharib; Ashley N Seiger; Amanda L Hayes; Reena Mehra; Sanjay R Patel
Journal:  Sleep       Date:  2014-04-01       Impact factor: 5.849

5.  Traditional and nontraditional cardiovascular risk factors in comorbid insomnia and sleep apnea.

Authors:  Faith S Luyster; Kevin E Kip; Daniel J Buysse; Aryan N Aiyer; Steven E Reis; Patrick J Strollo
Journal:  Sleep       Date:  2014-03-01       Impact factor: 5.849

Review 6.  Obesity and cardiovascular disease in women.

Authors:  Camila Manrique-Acevedo; Bhavana Chinnakotla; Jaume Padilla; Luis A Martinez-Lemus; David Gozal
Journal:  Int J Obes (Lond)       Date:  2020-02-17       Impact factor: 5.095

Review 7.  Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome.

Authors:  Badhma Valaiyapathi; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2018-03-19       Impact factor: 5.369

Review 8.  Obstructive sleep apnea, hypertension and cardiovascular diseases.

Authors:  C Gonzaga; A Bertolami; M Bertolami; C Amodeo; D Calhoun
Journal:  J Hum Hypertens       Date:  2015-03-12       Impact factor: 3.012

Review 9.  Obstructive Sleep Apnea Syndrome as a Trigger of Cardiac Arrhythmias.

Authors:  Julio Martí-Almor; Jesús Jiménez-López; Benjamin Casteigt; Javier Conejos; Ermengol Valles; Núria Farré; Miquel Félez Flor
Journal:  Curr Cardiol Rep       Date:  2021-02-20       Impact factor: 2.931

10.  The Effect of Supplemental Oxygen in Obesity Hypoventilation Syndrome.

Authors:  Juan F Masa; Jaime Corral; Auxiliadora Romero; Candela Caballero; Joaquin Terán-Santos; Maria L Alonso-Álvarez; Teresa Gomez-Garcia; Mónica González; Soledad López-Martínez; Pilar De Lucas; José M Marin; Sergi Marti; Trinidad Díaz-Cambriles; Eusebi Chiner; Miguel Merchan; Carlos Egea; Ana Obeso; Babak Mokhlesi
Journal:  J Clin Sleep Med       Date:  2016-10-15       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.